Drug Trial Radar · NCT07647783
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Jan 15, 2026
Primary completion
Feb 1, 2027
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- InnovStone Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.
Conditions
- Healthy Participants
Interventions
SYH2072 TabletsDrug
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 PlaceboDrug
SYH2072 placebo tablets will be administered as a single or multiple oral doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of Adverse eventsTime frame: Through study completion, an average of 8 months
- The rate of normality or abnormality of electrocardiogramTime frame: Through study completion, an average of 8 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.